Chloꢀ Vovard-Le Bray et al.
COMMUNICATIONS
[2] A. Donella-Deana, P. Ruzza, L. Cesaro, A. M. Brunati,
A. Calderan, G. Borin, L. A. Pinna, FEBS Lett. 2002,
523, 48–52.
[3] a) F. Brackmann, A. De Meijere, Chem. Rev. 2007, 107,
4538–4583; b) A. Trabocchi, D. Scarpi, A. Guarna,
Amino Acids 2008, 34, 1–24.
[4] a) S. Touchet, F. Carreaux, B. Carboni, A. Bouillon,
J. L. Boucher, Chem. Soc. Rev. 2011, 40, 3895–3914;
b) S. J. Baker, J. W. Tomshob, S. J. Benkovic, Chem.
Soc. Rev. 2011, 40, 4279–4285; c) J. N. Cambre, B. S. Su-
merlin, Polymer 2011, 52, 4631–4643, and references
cited therein.
[5] Peptide boronates are among the more potent reversi-
ble inhibitors of proteasome and Bortezomib, known
commercially as Velcade, the only hitherto boron-con-
taining drug, has been approved in 2003 for the treat-
ment of patients with relapsed or refractory multiple
[6] For some reviews on cycloisomerisation of enynes, see:
a) C. Aubert, O. Buisine, M. Malacria, Chem. Rev.
2002, 102, 813–834; b) G. C. Lloyd-Jones, Org. Biomol.
Chem. 2003, 1, 215–236; c) A. M. Echavarren, C.
Nevado, Chem. Soc. Rev. 2004, 33, 431–436; d) S. T.
Diver, A. J. Giessert, Chem. Rev. 2004, 104, 1317–1382;
e) L. AÇorbe, G. Dominguez, J. Pꢀrez-Castells, Chem.
Eur. J. 2004, 10, 4938–4943; f) C. Bruneau, Angew.
Chem. 2005, 117, 2380–2386; Angew. Chem. Int. Ed.
2005, 44, 2328–2334; g) L. Zhang, J. Sun, S. A. Kozmin,
Adv. Synth. Catal. 2006, 348, 2271–2296; h) E. Jimꢀnez-
NfflÇez, A. M. Echavarren, Chem. Rev. 2008, 108, 3326–
3350; i) V. Michelet, P. Y. Toullec, J.-P. GenÞt, Angew.
Chem. 2008, 120, 4338–4386; Angew. Chem. Int. Ed.
2008, 47, 4268–4315; j) S. I. Lee, N. Chatani, Chem.
Commun. 2009, 371–384.
[7] Reviews: a) S. Dꢀrien, P. H. Dixneuf, J. Organomet.
Chem. 2004, 689, 1382–1392; b) C. Vovard-Le Bray, S.
Dꢀrien, P. H. Dixneuf, C. R. Chim. 2010, 13, 292–303.
Papers: c) J. Le Paih, S. Dꢀrien, I. Özdemir, P. H. Dix-
neuf, J. Am. Chem. Soc. 2000, 122, 7400–7401; d) J.
Le Paih, C. Vovard-Le Bray, S. Dꢀrien, P. H. Dixneuf,
J. Am. Chem. Soc. 2010, 132, 7391–7397.
ly depends on the size of the created ring. More im-
portant geometrical constraints for the 5-membered
ring could explain this best diastereoselectivity.
In conclusion, we have opened a route for the syn-
thesis of novel highly strained bicyclic proline and pi-
pecolic acid derivatives via a stereoselective RuCl-
ACHTUNGTRENNUNG(C5Me5)ACHTUNGTRENNUNG(cod)-catalysed tandem carbene addition/cy-
clopropanation sequence. This one-pot catalytic pro-
cess leads to carboxylic and boronic amino acid deriv-
atives from easily accessible enynes in good yields
and under mild conditions. The cyclization reaction
was found to be tolerant with various N-protecting
groups, while the presence of hydrogen on the nitro-
gen atom prevents any cyclization. High Z stereose-
lectivities for the newly created alkenyl chain and ex-
cellent diastereoselectivities for proline derivatives
are observed. Further studies aimed at the synthesis
of enantiomerically enriched constrained a-amino
acids using this strategy are in progress, as is their in-
corporation into peptidomimetics.
Experimental Section
Typical Procedure for Catalytic Carbene Addition/
Cyclopropanation of Enynes
In a Schlenk tube under an inert atmosphere, to a solution
of the enyne (1 mmol) in degassed diethyl ether were added
1.2 mmol of a 2.0M (trimethylsilyl)diazomethane solution in
diethyl ether. 5 mol% of the precatalyst RuClACTHNUTRGENN(UG C5Me5)ACHTUNTGREN(NUGN cod)
were then introduced. The mixture was stirred at room tem-
perature for 3–5 h. Reaction completion was monitored
using GC or TLC techniques. The solvent was removed
under vacuum and diastereomers were separated as pure
compounds using standard chromatography over silica gel
with a diethyl ether/pentane eluting mixture.
All procedures and characterisation data are presented in
the Supporting Information.
[8] a) F. Monnier, D. Castillo, S. Dꢀrien, L. Toupet, P. H.
Dixneuf, Angew. Chem. 2003, 115, 5632–5635; Angew.
Chem. Int. Ed. 2003, 42, 5474–5477; b) F. Monnier, C.
Vovard-Le Bray, D. Castillo, V. Aubert, S. Dꢀrien, P. H.
Dixneuf, L. Toupet, A. Ienko, C. Mealli, J. Am. Chem.
Soc. 2007, 129, 6037–6049.
[9] a) M. Eckert, F. Monnier, G. T. Shchetnikov, I. D. Tita-
nyuk, S. N. Osipov, L. Toupet, S. Dꢀrien, P. H. Dixneuf,
Org. Lett. 2005, 7, 3741–3743; b) M. Eckert, S. Moulin,
F. Monnier, I. D. Titanyuk, S. N. Osipov, T. Roisnel, S.
Dꢀrien, P. H. Dixneuf, Chem. Eur. J. 2011, 17, 9456–
9462.
Acknowledgements
The authors are grateful to the CNRS and the Ministꢀre de la
recherche for support, the latter for a PhD grant to CV-LB
and HK. They thank Dr T. Roisnel, Centre de Diffractomꢁ-
trie X, UMR 6226-Institut des Sciences Chimiques de Rennes,
CNRS-Universitꢁ de Rennes 1, for performing the crystallo-
graphic analysis.
[10] a) G. L. Bolton, J. C. Hodges, J. R. Rubin, Tetrahedron
1997, 53, 6611–6634; b) C. M. Griffiths-Jones, D. W.
Knight, Tetrahedron 2010, 66, 4150–4166.
[11] a) N. A. Petasis, I. A. Zavialov, J. Am. Chem. Soc. 1997,
119, 445–446. b) For a recent review, see: N. R. Can-
deias, F. Montalbano, P. M. Cal, P. M. Gois, Chem. Rev.
2010, 110, 6169–6193.
References
[1] a) A. Giannis, T. Kolter, Angew. Chem. 1993, 105,
1303–1326; Angew. Chem. Int. Ed. Engl. 1993, 32,
1244–1267; b) J. Gante, Angew. Chem. 1994, 106, 1780–
1802; Angew. Chem. Int. Ed. Engl. 1994, 33, 1699–1720;
c) S. Hanessian, L. Auzzas, Acc. Chem. Res. 2008, 41,
1241–1251.
[12] B. Jiang, M. Xu, Org. Lett. 2002, 4, 4077–4080.
6
ꢁ 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Adv. Synth. Catal. 0000, 000, 0 – 0
ÝÝ
These are not the final page numbers!